Euro-NICE? Not Likely
This article was originally published in The Pink Sheet Daily
Executive Summary
European regulatory experts are looking for more collaboration among their health technology agencies and also between their HTAs and regulators, but results are likely to be limited and slow in coming.
You may also be interested in...
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
What Next In Oncology?
Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda?